Drugs / BR115
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06388902 | Feb 2024 → Aug 2028 | high grade malignant neoplasm | BioRay Pharmaceutical Co., Ltd. | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06388902 ↗ |
| Route | Subcutaneous | “BR115 for injection will be administered by subcutaneous injection” NCT06388902 ↗ |